Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

March 1, 2024

BENITEC BIOPHARMA INC.

3940 TRUST WAY

HAYWARD, CALIFORNIA 94545

March 1, 2024

VIA EDGAR

Doris Stacey Gama

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

 

Re:

Benitec Biopharma Inc.

Registration Statement on Form S-3 (File No. 333-277310)

Dear Ms. Gama:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-277310) so that it may become effective at 4:00 p.m. Eastern Time on March 5, 2024, or as soon thereafter as practicable.

 

Very truly yours,
BENITEC BIOPHARMA INC.
By:   /s/ Dr. Jerel Banks
  Name:   Dr. Jerel Banks
  Title:   Chief Executive Officer

 

cc:

Louis Rambo, Proskauer Rose LLP